H
H.J.T. Rutten
Researcher at Radboud University Nijmegen
Publications - 75
Citations - 3220
H.J.T. Rutten is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 28, co-authored 70 publications receiving 2824 citations.
Papers
More filters
Journal ArticleDOI
Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials
Vera Oppedijk,Ate van der Gaast,J. Jan B. van Lanschot,Pieter van Hagen,Rob M. van Os,Caroline M. van Rij,Maurice J.C. van der Sangen,Jannet C. Beukema,H.J.T. Rutten,Patty H. Spruit,Janny G. Reinders,Dick J. Richel,Mark I. van Berge Henegouwen,Maarten C.C.M. Hulshof +13 more
TL;DR: Preoperative CRT in patients with esophageal cancer reduced locoregional recurrence and peritoneal carcinomatosis and there was a small but significant effect on hematogenous dissemination in favor of the CRT group.
Journal ArticleDOI
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial
Anne J Breugom,W. van Gijn,E. W. Muller,Åke Berglund,C.B.M. van den Broek,Tone Fokstuen,Hans Gelderblom,Ellen Kapiteijn,Jan Willem H. Leer,Corrie A.M. Marijnen,Hendrik Martijn,E. Meershoek-Klein Kranenbarg,Iris D. Nagtegaal,Lars Påhlman,Cornelis J. A. Punt,Hein Putter,A. G. H. Roodvoets,H.J.T. Rutten,W.H. Steup,Bengt Glimelius,Bengt Glimelius,C.J.H. van de Velde +21 more
TL;DR: The PROCTOR-SCRIPT trial could not demonstrate a significant benefit of adjuvant chemotherapy with fluoropyrimidine monotherapy after preoperative (chemo)radiotherapy and TME on overall survival, disease-free survival, and recurrence rate.
Journal ArticleDOI
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Fariña-Sarasqueta,G. van Lijnschoten,Elna Moerland,G.J.M. Creemers,V.E.P.P. Lemmens,H.J.T. Rutten,A. J. C. Van Den Brule +6 more
TL;DR: The V600E BRAF mutation confers a worse prognosis to stage II and stage III colon cancer patients independently of disease stage and therapy.
Dutch colorectal cancer group. preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer
Ellen Kapiteijn,Corrie A.M. Marijnen,Iris D. Nagtegaal,Hein Putter,W. H. Steup,T. Wiggers,H.J.T. Rutten,Lars Påhlman,Bengt Glimelius,J.H.J.M. van Krieken,J.W.H. Leer,C.J.H. van de Velde +11 more
TL;DR: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized total mesorectal excision.
Journal ArticleDOI
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Bo Jan Noordman,Manon C.W. Spaander,Roelf Valkema,Bas P. L. Wijnhoven,Mark I. van Berge Henegouwen,Joel Shapiro,Katharina Biermann,Ate van der Gaast,Richard van Hillegersberg,Maarten C.C.M. Hulshof,Kausilia K. Krishnadath,Sjoerd M. Lagarde,Grard A. P. Nieuwenhuijzen,Liekele E. Oostenbrug,Peter D. Siersema,Peter D. Siersema,Erik J. Schoon,Meindert N. Sosef,Ewout W. Steyerberg,Ewout W. Steyerberg,J. Jan B. van Lanschot,Michael Doukas,Nanda C. Krak,Jan-Werner Poley,Caroline M. van Rij,Jaques Jghm Bergman,Suzanne S. Gisbertz,Hanneke W. M. van Laarhoven,Sybren L. Meijer,Lucas Goense,Nadia Haj Mohammad,Monique G.G. Hobbelink,G. Johan A. Offerhaus,Frank P. Vleggaar,Wouter L. Curvers,Geert-Jan Creemers,Mark J. Roef,Maurice J.C. van der Sangen,Jeroen Buijsen,Robert G. Riedl,Wendy M. J. Schreurs,Fabiënne A. R. M. Warmerdam,Mjr Janssen,Chella Van Der Post,Sandra A Radema,Camiel Rosman,H.J.T. Rutten +46 more
TL;DR: The correlation between clinical response during clinical response evaluations and the final pathological response in resection specimens was shown, as shown by the proportion of tumour regression grade (TRG) 3 or 4 residual tumours that was missed duringclinical response evaluations.